Top Forestry Stocks To Buy For 2015

Top Forestry Stocks To Buy For 2015: Entest Biomedical Inc (ENTB)

Entest BioMedical, Inc. (Entest), incorporated on September 24, 2008, is a development-stage company. During the fiscal year ended August 31, 2012, the Companys business consists of the development and commercialization of immunotherapeutic therapies for the veterinary market, as well as the acquisition and operation of veterinary hospitals. The Company is focusing its research and development efforts toward the development and commercialization of the ImenVax family of canine cancer vaccines. ImenVax I is a therapeutic for canine cancer, which involves isolating tumor cells from the patient and then placing the cells into a cell implant device that is inserted subcutaneously into the patient. ImenVax II, which utilizes cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses.

ImenVax

The Company is conducting a ten dog safety study to Evaluate ImenVax I for the Treatment of Canine Oral Mel anoma. As of May 17, 2012 three dogs suffering from oral melanoma have been administered the therapy with no dog suffering any material adverse reaction.

ImenVax II

The Company intends to include adjuvant cytokine along with tumor cells into the implantation device. The adjuvants can be added through cytokine expressing cell line.

ImenVax III

ImenVax III is intended to function by harnessing the ability of placental extracts to combat canine cancers. ImenVax III is intended to treat existing tumors through stimulation of immune responses to kill tumor cells directly; indirectly kill tumor cells by cutting off the tumor blood supply, and block the ability of the tumor to suppress the immune system.

ENT-576

ENT-57 is a therapy being developed by the Company for the treatment of Chronic Obstructive Pulmonary Disease (COPD), such therapy consists of extracting a therapeutic number of ce! lls from a tiss ue containing in part a stem cell population; processing sai! d population of cells derived from said tissue so as to concentrate said stem cell population; systemic re-administration of said cell population into the same patient, and exposing the patient lung to a sufficient intensity and frequency of laser irradiation necessary to augment therapeutic activity of said cells in said patient suffering from COPD. A therapeutic intervention in COPD would require addressing the issues of inflammation and regeneration.

Advisors' Opinion:

• [By Peter Graham]

  Small cap mining stocks US Tungsten Corp (OTCMKTS: USTU) and LKA Gold Inc (OTCMKTS: LKAI) along with biotech Entest BioMedical Inc (OTCMKTS: ENTB) have been getting some attention lately in various investment newsletters with at least one of these stocks being the subject of paid promotions while another could soon be the subject of an investor relations campaign. But will any of these small cap stocks be winners for investors or traders? Here is a quick reality check:

• [By Bryan Murphy]

  The so-called fundamentals, frankly, don't really matter for Entest BioMedical Inc. (OTCMKTS:ENTB) or Gevo, Inc. (NASDAQ:GEVO). Oh, both GEVO and ENTB are generating sales, but both are consistently taking losses. That's ok though, as for both companies right now, profits aren't really the point - it's the pipeline that matters.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-forestry-stocks-to-buy-for-2015.html